---
title: "万邦德医药控股集团股份有限公司 (002082.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/002082.SZ.md"
symbol: "002082.SZ"
name: "万邦德医药控股集团股份有限公司"
industry: "制药"
---

# 万邦德医药控股集团股份有限公司 (002082.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.chinawepon.com](https://www.chinawepon.com) |

## Company Profile

公司主营业务为医药制造、医疗器械为主的大健康产业，为深圳主板医药制造上市公司，总部位于浙江台州温岭。公司始终坚持以科技为先导，拥有完善的研发体系和一支具有较高专业技术水平及自主创新能力的研发团队，并建立有 “中国药科大学——万邦德中药现代化联合研究中心”、“浙江大学——万邦德中药现代化联合研究中心”、“心脑血管药物省级高新技术企业研究开发中心”、“模范院士专家工作站” 等研发平台公司医药制造业务主要从事现代中药、化学原料药及化学制剂的研发、生产和销售;医疗器械业务主要从事骨科植入器械、一次性无菌医用高分子器械的研制、生产与销售，医疗器械设备代理与维保服务、医院机构一体化交钥匙解决方案综合服务等...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:10.000Z

**Overall: C (0.56)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 101 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.26% |  |
| Net Profit YoY | -86.06% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.08 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10.92B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.39B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.53% | D |
| Profit Margin | 1.02% | C |
| Gross Margin | 32.39% | C |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.26% | E |
| Net Profit YoY | -86.06% | E |
| Total Assets YoY | 6.41% | B |
| Net Assets YoY | 0.11% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 9762.76% | A |
| OCF YoY | -13.26% | E |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.31 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 39.09% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 万邦德医药控股集团股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.53%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "1.02%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "32.39%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.26%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-86.06%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.41%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.11%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "9762.76%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-13.26%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.31",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "39.09%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 768.77 | 158/222 | 590.04 | 125.40 | 82.91 |
| PB | 4.08 | 170/222 | 3.29 | 2.00 | 1.38 |
| PS (TTM) | 7.87 | 161/222 | 6.43 | 3.94 | 2.61 |
| Dividend Yield | 0.00% | - | 1.40% | 1.34% | 1.17% |

## References

- [Company Overview](https://longbridge.com/en/quote/002082.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/002082.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/002082.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.